Veracyte, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VCYT research report →
Range $44 – $65
Price Chart
About the company
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
- CEO
- Marc Stapley
- IPO
- 2013
- Employees
- 755
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on VCYT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.03B
- P/E
- 15.81
- Fwd P/E
- 13.05
- PEG
- 0.05
- P/S
- 3.49
- P/B
- 1.41
- EV/EBITDA
- 14.08
- Div Yield
- 0.00%
- Gross Margin
- 72.35%
- Op Margin
- 15.36%
- Net Margin
- 21.80%
- ROE
- 9.27%
- ROIC
- 5.97%
Latest fiscal year · YoY change
- Revenue
- $517.14M+16.0%
- Gross Profit
- $360.05M+20.8%
- Op Income
- $74.15M
- Net Income
- $66.35M+174.9%
- EPS
- $0.84+162.5%
- OCF Growth
- +81.5%
- FCF Growth
- +98.5%
- 52W High
- $60.91
- 52W Low
- $21.91
- 50D MA
- $40.72
- 200D MA
- $42.13
- Beta
- 1.96
- RSI (14)
- 31
- Avg Volume
- 1.86M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Veracyte beat third-quarter expectations on revenue, margin and cash generation, but cut near-term Decipher volume expectations and signaled a more moderated growth profile for 2027.· November 4, 2026
- Q3 revenue rose 15% year over year to $152 million, with non-GAAP gross margin at 73.7% and adjusted EBITDA at $41.2 million, or 27.2% of revenue.
- Decipher prostate volume grew 12% to nearly 30,000 tests, but was about 1,000 tests below expectations; management reset incremental annual volume growth to 12,000-15,000 tests.
- Afirma was a standout, with volume up 12% to about 19,000 tests and revenue up 19%, helped by lower no-result rates from the V2 transcriptome workflow.
- Prosigna launched in the U.S. with encouraging early demand and Medicare coverage for qualifying postmenopausal patients; international Prosigna revenue grew 40%.
- The company acquired Convergent Genomics and is expanding its bladder portfolio, while the board authorized up to $100 million of share repurchases.
Third-quarter revenue increased 15% year over year to $152 million. Testing revenue grew 15% to $146 million, testing volume increased 13% to 49.5 thousand tests, and total volume increased 15% to approximately 52.7 thousand tests. Non-GAAP gross margin was 73.7%, up 90 basis points year over year, and testing gross margin was 74.7%, up about 70 basis points. Adjusted EBITDA was $41.2 million, or 27.2% of revenue, and GAAP net income was $31.5 million. Cash from operations was $40.3 million, and quarter-end cash, cash equivalents and short-term investments were $371 million after a $150 million cash payment for Convergent Genomics. For full-year 2026, Veracyte raised revenue guidance to $590 million-$593 million from $590 million-$596 million previously, and said testing revenue should be $571 million-$573 million. The company now expects Afirma revenue growth of 16%, Decipher prostate revenue growth of 16%, about $10 million in other testing revenue, and adjusted EBITDA above 26%. Looking to 2027, management said it currently expects Decipher volume growth near the 12,000 incremental-test floor, about 5% Afirma volume growth, 10% total volume growth, mid-single-digit total revenue growth, and 22% adjusted EBITDA for the full year, with margins improving to 25% as it exits the year.
Marc Stapley said the quarter reinforced Veracyte’s long-term opportunity despite a softer-than-expected Decipher volume outcome. He framed the Decipher reset as normalization after two years of outsized growth driven by guideline changes, while emphasizing new predictive data in prostate cancer and ongoing studies across the risk continuum. He was upbeat about Afirma’s momentum, Prosigna’s early launch traction, and the expanding bladder portfolio, and repeatedly stressed that evidence generation and new clinical claims remain central to the strategy.
Rebecca Chambers highlighted the financial quality of the quarter: revenue up 15% to $152 million, non-GAAP gross margin of 73.7%, adjusted EBITDA of $41.2 million, and $40.3 million of operating cash flow. She pointed to operational efficiency, better ASP, and the V2 transcriptome workflow as margin drivers, while noting higher R&D and sales and marketing spend tied to product development and the new Prosigna team. On outlook, she narrowed 2026 revenue guidance, lifted Afirma growth guidance to 16%, and said 2027 should still generate 22% adjusted EBITDA even with higher Decipher sales investment, with upside possible from prior-period collections and ASP strength. She also noted the board authorized up to $100 million of share repurchases.
Analysts pressed management on why Decipher growth was falling short and whether the slowdown was structural. Management said the main factors were normalization after guideline-driven acceleration, lower growth in low-risk patients, and distraction from digital pathology competition, but stressed Decipher is still growing and gaining share; they plan a 30% increase in the urology commercial team to address it. Questions on Prosigna focused on Medicare’s narrower coverage versus the trial’s strongest data in premenopausal and higher-node patients; management said an LCD expansion would take time, that commercial coverage is key for premenopausal patients, and that the published OPTIMA data should help. Analysts also asked how the company can keep profitability high while adding reps, and management replied that shared lab and billing infrastructure, plus ongoing operating efficiencies and prior-period collections, should support margins.
The company delivered solid top-line growth, strong profitability, and meaningful cash generation, while Afirma and early Prosigna demand both showed momentum. Management believes new prostate evidence, expanding bladder products, and commercial investments can sustain double-digit company-wide growth over time.
Decipher, the biggest product, missed volume expectations again and management reset its annual incremental growth assumption to 12,000-15,000 tests, with 12,000 now treated as the floor. The company also signaled that 2027 will be a transition year with mid-single-digit revenue growth, reflecting slower Decipher growth, tough prior-period collection comps, and modest early revenue contribution from newer products.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.4%
- Shares Outstanding
- 80.70M
- Float Shares
- 80.19M
of shares held by institutions
379 13F filers
Buy/sell ratio 0.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for VCYT, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | Mar 3, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Feb 18, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Nov 12, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jun 16, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Oct 16, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Sep 15, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Apr 10, 23 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Dec 23, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Dec 10, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Dec 8, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Oct 29, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jan 17, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Dec 24, 19 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Dec 12, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 13.49M | ▲ 313.82K |
| Vanguard Group Inc | 8.50M | ▼ 77 |
| Fmr LLC | 6.51M | ▼ 1.19M |
| Artisan Partners Limited Partnership | 5.54M | ▲ 42.03K |
| State Street Corp | 5.53M | ▲ 834.61K |
| Vanguard Portfolio Management LLC | 4.72M | ▲ 271.46K |
| Vanguard Capital Management LLC | 3.59M | ▲ 61.69K |
| William Blair Investment Management, LLC | 2.71M | ▲ 1.28M |
| Dimensional Fund Advisors LP | 2.69M | ▼ 135.40K |
| Gw&K Investment Management, LLC | 2.41M | ▲ 992.76K |
| Ark Investment Management LLC | 2.30M | ▼ 757.87K |
| Wellington Management Group Llp | 2.27M | ▼ 284.13K |
Held by 544 ETFs
Biggest fund positions in VCYT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 28, 26 | Wygant Jonathan | other | 1,306 |
| Oct 27, 26 | Holstein Jens | other | 7,500 |
| Sep 24, 26 | Holstein Jens | other | 7,500 |
| Oct 27, 26 | Holstein Jens | sell | 7,500 |
| Sep 24, 26 | Holstein Jens | sell | 7,500 |
| Oct 27, 26 | Holstein Jens | other | 7,500 |
| Oct 27, 26 | EASTHAM KARIN | other | 10,000 |
| Oct 27, 26 | EASTHAM KARIN | sell | 14,850 |
| Oct 27, 26 | EASTHAM KARIN | other | 10,000 |
| Oct 19, 26 | Bhanji Muna | sell | 1,864 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VCYT coverage
Recent articles, reports, and earnings notes.
Want a deeper read on VCYT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Artisan Global Discovery Fund Q3 2026 Portfolio Activity
seekingalpha.com · Nov 18
Veracyte (VCYT) Securities Investigation Notice - Levi & Korsinsky
prnewswire.com · Nov 12
Veracyte: Solid Profits, Slowing Tests, And A Stock In Limbo
seekingalpha.com · Nov 12
Veracyte, Inc. (VCYT) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 10
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Veracyte (VCYT)
globenewswire.com · Nov 10
VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law
businesswire.com · Nov 9
Veracyte (NASDAQ:VCYT) Sees Unusually-High Trading Volume – Still a Buy?
defenseworld.net · Nov 8
Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment
zacks.com · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
